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Abstract
Background: Ratios of bacteriologically positive tuberculosis (TB) prevalence to notification rates are used to
characterise typical durations of TB disease. However, this ignores the clinical spectrum of tuberculosis disease and
potentially long infectious periods with minimal or no symptoms prior to care-seeking.
Methods: We developed novel statistical models to estimate progression from initial bacteriological positivity
including smear conversion, symptom onset and initial care-seeking. Case-detection ratios, TB incidence, durations,
and other parameters were estimated by fitting the model to tuberculosis prevalence survey and notification data
(one subnational and 11 national datasets) within a Bayesian framework using Markov chain Monte Carlo methods.
Results: Analysis across 11 national datasets found asymptomatic tuberculosis durations in the range 4–8 months
for African countries; three countries in Asia (Cambodia, Lao PDR, and Philippines) showed longer durations of > 1
year. For the six countries with relevant data, care-seeking typically began half-way between symptom onset and
notification. For Kenya and Blantyre, Malawi, individual-level data were available. The sex-specific durations of
asymptomatic bacteriologically-positive tuberculosis were 9.0 months (95% credible interval [CrI]: 7.2–11.2) for men
and 8.1 months (95% CrI: 6.2–10.3) for women in Kenya, and 4.9 months (95% CrI: 2.6–7.9) for men and 3.5 months
(95% CrI: 1.3–6.2) for women in Blantyre. Age-stratified analysis of data for Kenya showed no strong age-
dependence in durations. For Blantyre, HIV-stratified analysis estimated an asymptomatic duration of 1.3 months
(95% CrI: 0.3–3.0) for HIV-positive people, shorter than the 8.5 months (95% CrI: 5.0–12.7) for HIV-negative people.
Additionally, case-detection ratios were higher for people living with HIV than HIV-negative people (93% vs 71%).
Conclusion: Asymptomatic TB disease typically lasts around 6 months. We found no evidence of age-dependence,
but much shorter durations among people living with HIV, and longer durations in some Asian settings. To
eradicate TB transmission, greater gains may be achieved by proactively screening people without symptoms
through active case finding interventions
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Background
Population surveys of the prevalence of bacteriologically-
positive tuberculosis (TB) disease are a key tool for un-
derstanding TB epidemiology and burden, and, when re-
peated over time, for monitoring the impacts of control
efforts. (Bacteriologically-positive TB is TB that is diag-
nosed with a positive result to any bacteriological test:
sputum smear, culture or Xpert.) Over the last decade,
the World Health Organization (WHO) has encouraged
and facilitated a series of nationally-representative TB
prevalence surveys in priority countries [1]. Standardisa-
tion of methodology and reporting for TB prevalence
surveys has been aided by the publication of WHO guid-
ance [2], and detailed methods and results for national
TB prevalence surveys are usually published as reports
and peer-reviewed articles. TB prevalence surveys are a
particularly important source of data for estimating TB
incidence in high-burden settings where notification sys-
tems are imperfect [1], and while typically powered to
achieve a 20% relative precision in the measurement of
TB prevalence [2], surveys also contain additional infor-
mation on subgroups which has, for instance,
highlighted the higher burden of TB among men [3].
By comparing prevalence with notifications—usually
as a prevalence-to-notification (P:N) ratio—one can esti-
mate a typical timescale for prevalent TB, the inverse of
which (the patient diagnostic rate) provides a measur-
able indicator of the effectiveness of case detection [4].
Comparing P:N ratios between sexes has shown men
have poorer access to care in many settings [3]. How-
ever, the influence of age and HIV have not been
analysed.
Several prevalence surveys also record whether indi-
viduals with TB were symptomatic and some record
whether individuals with TB had previously sought care
for their symptoms [5]. These surveys have found that
large proportions of cases—around half—do not report
symptoms [6, 7]. Lack of symptoms among those with
microbiologically-confirmed pulmonary TB has contrib-
uted to an increased understanding of asymptomatic and
subclinical TB as being part of a spectrum of TB disease
[8], and a potentially important contributor to TB bur-
den and transmission [7].
Many aspects of the natural history of TB disease prior
to (or without) treatment remain very uncertain because
ethical considerations mean we must rely on historic
data from the pre-chemotherapy era. For example, how
often and how quickly individuals with smear-negative
TB progress to smear-positive disease is unclear. Simi-
larly, while there are data to suggest a typical duration of
around three years for untreated TB disease [9], there is
only weak and indirect data to quantify the duration of
TB among people living with HIV (PLHIV), which is
thought to be much shorter [10].
We therefore sought, as our primary focus, to leverage
prevalence survey data from a variety of settings to
estimate the duration of asymptomatic TB disease and
typical delays to care-seeking and notification. Hypothe-
sising an influence of sex, age and HIV infection status
on these quantities, our primary objectives also included
stratified analyses where data allowed. We used a novel
Bayesian framework within which we incorporated un-
certainty, disease progression before detection, and
trends in incidence. This approach also provided, as by-
products, estimates of TB incidence, incidence trends,
and case-detection ratios, which we also report as
secondary outcomes.
Methods
Study populations and data
TB prevalence surveys
We analysed data from eleven national and one sub-
national setting with a TB prevalence survey conducted
after 2010. We excluded TB prevalence surveys that re-
lied solely on symptom screening to decide who to sam-
ple for bacteriological testing and restricted to the
population aged 15 years or older.
The eleven national settings with recent TB prevalence
surveys are Cambodia [11], Ethiopia [12], Kenya [13],
Lao PDR [14], Malawi [15], Pakistan [16], Philippines
[17], Tanzania [5, 18], Ugand a[19], Vietnam [20], and
Zambia [21]. For those prevalence surveys, we extracted
the raw counts of eligible subjects and active cases,
excluding those already on TB treatment if possible.
Seven surveys included healthcare behaviour data enab-
ling us to identify whether symptomatic cases had
started seeking care.
Summaries of prevalence survey data are shown in the
upper part of Table 1. The proportion of prevalent cases
that were asymptomatic ranged from 30% in Malawi, to
70% in Cambodia, and the proportion of prevalent cases
that were sputum smear-positive varied from 23% in
Vietnam to 84% in Tanzania. Definitions used for symp-
toms, care-seeking, and raw counts extracted from the
prevalence are summarised in Additional file 2.
The sub-national TB prevalence survey from Blantyre,
Malawi, and the national survey from Kenya included in-
dividual data, allowing analysis by smear status, age, and
HIV status [13]. In Blantyre, Malawi, the prevalence sur-
vey was conducted as part of a community cluster ran-
domised trial across approximately 750,000 adults in 72
densely populated neighbourhoods of the city. For Blan-
tyre, we aligned symptom definition with that of Kenya
by considering cough of ≥ 2 weeks, considering cough of
any duration in a sensitivity analysis.
In 2019, a TB prevalence survey was carried out in
Blantyre as part of a cluster-randomised trial of
community-based TB screening interventions (ISRC
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Table 1 Epidemiological estimates. World Health Organization (WHO) case detection ratio (CDR), our CDR, proportions of cases
dying and self-curing before treatment, rates of decline by setting
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TN11400592). Blantyre City was demarcated into 72
neighbourhood clusters, each with approximately 4000
adults aged 15 years or older. All households were enu-
merated and 115 households per cluster were chosen at
random for participation into the prevalence survey,
with the aim of recruiting 215 adults (≥ 15 years old) per
neighbourhood. Adults from the randomly selected
households were visited and invited to visit a study tent
where TB symptom screening and digital chest radio-
graph (interpreted by radiographers and computer-
assisted diagnostic software [Qure.ai version 2.0]) were
done. Participants who had an abnormal chest X-ray or
reported cough of any duration were asked to provide
two spot sputum samples for Xpert, smear microscopy,
and MGIT culture, and participants with positive results
were linked to treatment.
Definitions
Unless otherwise stated, we used the definition of TB
symptoms and health-care seeking adopted by each TB
prevalence survey (see Additional file 2). Asymptomatic
TB was taken to be bacteriologically-positive pulmonary
TB in those reporting no TB symptoms, and we as-
sumed no health-care seeking for TB during this phase.
Participants with prevalent TB who were already taking
TB treatment were excluded. We assumed TB treatment
initiation, TB confirmation, and case notification are
identical events for the modelling.
TB notification data
We used TB notification data and treatment outcome
data from the WHO TB database for the countries with
national prevalence surveys [5, 11–21]. We included
new and relapse TB regardless of smear status since
2013. We applied the proportions of HIV among TB no-
tifications by sex, age group, and smear status to disag-
gregate the WHO notification data. Where notification
data exhibited level shifts suggestive of changes in
reporting, only consistent, sequential data were used (see
graphs in Additional file 1).
In order to take advantage of the finer-grained preva-
lence data for Kenya and Blantyre, Malawi, we sought
correspondingly stratified notification data. For Kenya,
we obtained data simultaneously stratified by HIV and
age group from the National Tuberculosis Programme.
For Blantyre, we obtained individual-level notification
data from an enhanced surveillance system. We matched
the age-groups of the Kenya data to the finest scale of
WHO case notification data; for Blantyre, Malawi, with
lower case counts, we used two age groups (15 to 49,
and 50+ years).
Demographic data
In order to model mortality and project national
numbers of prevalent cases to relate to notifications,
we used age- and sex-specific background mortality
rates and population sizes from 2019 World Popula-
tion Prospect (WPP) data, using the mid-year popula-
tion estimates [22]. For Blantyre, we rescaled the
Malawi demographic data to local 2008 and 2018
population censuses [23, 24].
Additional file 2 details the extracted data and infor-
mation from the prevalence surveys, and the demo-
graphic and notification data to replicate the analysis are
available at Addition file 3, 4 and 5.
Statistical methods
Estimation of TB progression and care-seeking behaviour
We developed three state transition models of TB case-
detection to match available data, and fitted them to
estimate parameters driving TB progression and care-
seeking behaviour. Figure 1 shows that all models con-
tain an asymptomatic phase and progress to the symp-
tomatic phase. Model A presents a basic transition
between asymptomatic/symptomatic phases; Model B di-
vides the symptomatic phase by presence of care-seeking
intentions, and Model C details the conversion between
smear-negative and smear-positive and care-seeking by
smear status. Model B is only applicable to the preva-
lence surveys that reported care-seeking behaviours. We
Table 1 Epidemiological estimates. World Health Organization (WHO) case detection ratio (CDR), our CDR, proportions of cases
dying and self-curing before treatment, rates of decline by setting (Continued)




































































aValues are crude rates or proportions with 95% Binomial confidence intervals, while the model estimates are mean estimators with 95% credible intervals
bP:N ratios use prevalence from the model estimates for 2019 and notified cases from WHO 2019 TB notification data
cCase-detection ratio is defined as the ratio of notified cases and the estimated incident cases in percentage
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did not combine Model B and C because the symptoms,
smear status, and care-seeking behaviours prevalence
surveys were not cross-tabulated in the published re-
ports. We constructed a likelihood depending on these
states for fitting to TB prevalence and case-notification
data. For Kenya and Blantyre data with Model C, we in-
corporated proportional hazard models relating the rate
of developing symptoms and the care-seeking rates by
smear status to covariates of age, sex, and HIV status.
The choice of model type used was determined by which
data were available in the prevalence survey. These
model structures follow the usual structures used in
conventional ordinary differential equation TB models
to describe the progression and detection or prevalent
TB, e.g. the smear status-stratified model introduced by
Dye et al. [25], but also including symptom and care-
seeking progression similarly to Dowdy et al. [26]
We calculated a single weighted-mean background
mortality rate from WPP data in each country, using
WHO TB notifications as weights. For the analyses with
HIV stratification, we added HIV-related deaths for
PLHIV from the UNAIDS database: 0.016 per year
(21,000/1,300,000) for Kenya in 2016 and 0.011 per year
(11,000/1,000,000) for Blantyre (based on Malawi data).
In asymptomatic TB, we assumed no TB-related deaths,
but did allow self-cure and deaths due to other causes.
Smear status-specific TB death rates were applied to
symptomatic TB states based on Tiemersma et al. [9].
For Model A and Model B, regardless of smear status,
we applied the untreated TB deaths weighted by smear
status in the notification data. We conducted sensitivity
analyses for assumed excess mortality rates of
asymptomatic/symptomatic TB. We also considered two
extreme assumptions for HIV-TB excess mortality: the
same TB mortality rate as HIV-negative people, and an
excess mortality rate of 5% per month as considered in
Vynnycky et al. [27] for gold miners in South Africa. Fi-
nally, we considered the impact on estimates of fitting to
data from mis-specified models allowing symptom
reversion.
We assumed each state declined exponentially with a
constant shared rate. The statistical models were con-
structed within a Bayesian framework; Additional file 1
details the mathematical formulation and priors. We fit-
ted all models by Markov chain Monte Carlo (MCMC)
using R with RStan. Inferences were based on 3000 sam-
ples from three chains. For each chain, we set at least
4000 burn-in steps and increased thinning to ensure the
effective sample sizes are larger than 10% of sample
sizes. Processed data, all source code, and detailed diag-
nostics for this analysis are available on Github as
[https://github.com/TimeWz667/AsymTB].
Metrics calculated
For each setting, we used posterior samples to calculate:
the TB incidence; the mean durations of asymptomatic
disease, disease without case-seeking initiation (where
applicable), and prevalent untreated disease; the case de-
tection ratio (CDR; defined as the ratio of estimated inci-
dence rates and observed notification rates) as the ratio
of incidence and notification rates; and the proportion of
TB cases reaching each stage of care (assuming unidirec-
tional progression through states). Aggregated quantities
were computed weighted by model-estimated incidence.
Fig. 1 Diagrams of model structure. White boxes are states representing all bacteriologically-positive TB accessible to prevalence surveys, with
structure matched to available data. Dashed arrows represent transitions out of active disease, either through self-cure or death. Models are
additionally stratified by sex, and for Kenya and Blantyre, Malawi by age and HIV in addition
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We also output a joint posterior for the proportion of
symptomatic cases initially smear-positive and the subse-
quent smear-conversion rate. We report means and 95%
credible intervals (CrIs).
Results
MCMC runs all converged with Gelman-Rubin R^2 sta-
tistics < 1.05. Supplementary data on convergence and
parameter posteriors are presented in Additional file 1.
Duration of asymptomatic disease, time without care-
seeking initiation and time to case-detection
The national estimates for duration of asymptomatic dis-
ease typically ranged around 3–8 months. However,
three countries in Asia (Lao PDR, Cambodia,
Philippines) showed longer durations of over one year
(see Fig. 2). These countries also had long total dura-
tions: 22 months for Cambodia and Philippines, and
three years for Lao PDR. Only one country (Ethiopia)
had a total duration lower than 12months. In the seven
countries where we could estimate the delay to care-
seeking initiation, apart from the Philippines (16
months), delay varied between 1.2 (0.7–1.9) months for
Cambodia and 6.6 (95% CrI: 4.8–8.6) months for
Malawi. The asymptomatic phase represented between
27% and 63% of time as a prevalent case, and care-
seeking occurred between 15% and 59% of the way
between the first symptom developed and notification
(or death or self-cure).
Development of smear-positivity
Figure 3 shows the joint posterior probability densities
of smear conversion rates and the proportion of symp-
tomatic cases that were smear-positive at symptom on-
set. Estimates of smear conversion rates were linearly
related to the initial proportion of symptomatic cases
that were smear-positive. Pooling weighted by TB notifi-
cations in 2019 (excluding Malawi and Vietnam as out-
liers) yielded a gradient of 0.239 years, and a pooled
intercept of 53.4% smear-positive (for zero smear
conversion rate).
Estimates of epidemiological indices considering
asymptomatic phase of TB
Table 1 shows the empirical estimates of total duration
and total asymptomatic duration based on P:N ratios.
Fig. 2 Total time in months spent in each state during bacteriologically-positive TB disease. ‘Not diagnosed’ includes all states (white boxes) in
Fig. 1. Median and 95% quantiles are shown as points and error bars, respectively. Posterior distributions are shown by coloured kernel
density estimates
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Fig. 3 Smear-conversion rate and initial proportion smear-positive in symptomatic bacteriologically-positive TB disease. A joint posterior
probability densities of initial proportion smear-positive (y-axis) and hazard of converting from smear-negative to smear-positive (x-axis) in
symptomatic bacteriologically-positive TB by country, based on Model 3. B the correlation of percentage smear-positive at symptom onset and
smear-type conversion rate. X-axis indicates the slopes of A estimated by linear regression (KHM = Cambodia, ETH = Ethiopia, KEN = Kenya, LAO
= Lao People’s Democratic Republic, MWI = Malawi, PAK = Pakistan, PHL = Philippines, TZA = United Republic of Tanzania, UGA = Uganda, VNM
= Viet Nam, ZMB = Zambia) (C) joint probability density of initial proportion smear-positive (y-axis) and hazard of converting from smear-negative
to smear-positive (x-axis) pooled by weights of notified cases in 2019 (excluding Malawi and Vietnam as outliers)
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Empirical estimates of duration systematically overesti-
mate the durations (see also direct comparison of add-
itional results in Additional file 1), because they
implicitly assume all episodes of TB disease end in noti-
fication. Modelling self-cure and death leads to shorter
estimates of duration and differences in estimated CDRs
from WHO estimates. The proportions of incident TB
who die or self-cure before being detected are shown in
Table 1. Estimates of TB incidence are also distinct but
comparable to WHO incidence estimates. We estimated
rates of TB incidence change from a decline of 7.3%
(95% CrI: 7.1–7.5%) per year in Ethiopia up to an
increase of 8.3% (95% CrI: 8.2–8.4%) per year in the
Philippines.
Care-seeking cascade estimates
Figure 4 shows care cascade estimates for the year of
national prevalence surveys, showing the proportion of
incident TB cases that develop symptoms, begin seeking
care, initiate treatment, and finally successfully complete
treatment, assuming unidirectional progression. There
were notable differences between countries, with the
proportion initiating TB treatment ranging from 30%
(95% CrI: 24–38%) in Lao PDR to 83% (95% CrI: 72–
88%) in Ethiopia. Versions of these figures with cohort
timings are shown in Additional file 1.
Sex, age, and HIV
For Kenya and Blantyre, Malawi, we were able to
examine results stratified by sex, age, and HIV-status
(see Table 2). For Kenya we found total durations of
18.8 months (95% CrI: 16.1–21.8) for men and 15.4
months (95% CrI: 13.0–18.1) for women, and for Blan-
tyre 9.9 months (95% CrI: 6.7–13.8) for men and 6.6
months (95% CrI: 3.5–10.2) for women, in line with pre-
vious work suggesting longer durations for men [3].
Adjusted results for Kenya suggested longer durations
asymptomatic in men than women; however, there were
Fig. 4 Healthcare cascade. The values are the fraction of the incident cohort reaching each stage. The second bars may be missing if the TB
prevalence survey did not report results on care-seeking behaviour
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no clear differences in unadjusted results and results
from Blantyre (see risk ratios in Table 2). There were
also no clear patterns with respect to age. However, HIV
status had a strong effect, with asymptomatic and symp-
tomatic durations being shorter in PLHIV than those
that were HIV negative. The total duration in PLHIV
was 3.7 months (95% CrI: 1.9–6.0) for Blantyre and 7.8
months (95% CrI: 5.8–10.2) for Kenya. We found that
CDRs were consistently higher in PLHIV than in those
without HIV infection, even with higher deaths rates for
PLHIV with TB assumed (Table 3).
Sensitivity analyses
Across all mortality scenarios considered (Additional file
1-Section E), differences in duration were around one
month, except for Lao PDR. The highest levels of as-
sumed mortality led to up to a 7 percentage-point lower
case-detection ratio than for the lowest assumed mortal-
ity. Sensitivity analysis assuming an extremely high ex-
cess TB mortality for PLHIV (Table 3) led to up to 15
percentage-point lower CDRs and correspondingly
higher incidence rates. However, for both Kenya and
Blantyre, the case-detection ratios were still not lower
than that of HIV negative populations. Considering a
broader range of symptoms resulted in shorter durations
of the asymptomatic phase but longer time-spent on
care-seeking given the TB prevalence survey and notifi-
cation data. Estimates of rates of progression to symp-
toms were systematic under-estimates in the presence of
symptom reversion, with an error that depended roughly
linearly on reversion rate (with gradient of prevalent
symptomatic TB over asymptomatic TB). The time
asymptomatic and time symptomatic were both system-
atic over-estimates with symptom reversion.
Discussion
By calibrating simple models of TB disease and care-
seeking progression to prevalence survey and notifica-
tion data, we were able to infer the typical duration of
asymptomatic bacteriologically-positive TB to be around
six months. However, there is a large variation between
settings, with longer durations of asymptomatic disease
in the included Asian settings. The asymptomatic phase
typically comprised around half the total time before no-
tification. For countries that reported care-seeking his-
tory in their prevalence surveys, we were able to
estimate the average timing of initial care-seeking, find-
ing this was approximately halfway between becoming
symptomatic and ultimate diagnosis. We found limited
evidence of age-dependence in overall durations, with a
hint of longer durations in older age groups, but did find
substantially shorter disease durations in people living
Table 2 Covariate analysis for symptom development rate for Kenya and Blantyre. Asymptomatic, symptomatic and total TB










Crude rate Crude RR Adjusted RR
Kenya Overall 8.3 (6.8–10.1) 1.25 (1.05–1.50) 8.4 (7.1– 9.7) 16.7 (14.5–19.1)
Sex Female 8.1 (6.2–10.3) 1.30 (1.01–1.69) Reference Reference 7.2 (5.8–8.8) 15.4 (13.0–18.1)
Male 9.0 (7.2–11.2) 1.14 (0.93–1.40) 0.89 (0.63–1.20) 0.68 (0.50–0.89) 9.7 (8.2–11.5) 18.8 (16.1–21.8)
Age (15,25) 9.5 (6.6–13.0) 1.11 (0.76–1.60) reference reference 10.4 (7.9–13.2) 20.0 (16.1–24.4)
(25,35) 8.6 (6.3–11.4) 1.23 (0.90–1.66) 1.13 (0.75–1.67) 1.20 (0.77–1.69) 9.4 (7.5–11.5) 18.0 (15.0–21.6)
(35,45) 7.1 (5.0– 9.7) 1.55 (1.08–2.22) 1.43 (0.87–2.17) 1.72 (1.10–2.54) 7.7 (5.9– 9.7) 14.7 (11.9–18.1)
(45,55) 7.4 (4.8–10.7) 1.49 (0.94–2.31) 1.39 (0.80–2.43) 1.82 (0.95–3.17) 8.3 (6.0–11.1) 15.7 (12.4–19.7)
(55,65) 9.6 (6.1–13.7) 1.10 (0.70–1.74) 1.02 (0.55–1.72) 1.23 (0.68–2.06) 5.2 (3.1–8.3) 14.8 (10.9–19.4)
(65,Inf) 7.1 (4.6–10.2) 1.52 (0.97–2.35) 1.43 (0.80–2.55) 1.42 (0.89–2.34) 5.3 (3.4–7.7) 12.4 (9.4–16.0)
HIV Non-HIV 9.8 (7.9–12.2) 1.03 (0.85–1.25) Reference Reference 9.9 (8.5–11.7) 19.7 (17.1–23.0)
PLHIV 3.8 (2.4–5.6) 3.09 (1.96–4.80) 2.88 (1.82–4.54) 2.45 (1.45–3.68) 4.0 (2.5–5.7) 7.8 (5.8–10.2)
Blantyre Overall 3.8 (2.3–5.8) 3.10 (1.86–4.98) 3.7 (2.3–5.4) 7.5 (5.4–10.1)
Sex Female 3.5 (1.3–6.2) 3.90 (1.73–8.83) reference reference 3.1 (1.3–5.5) 6.6 (3.5–10.2)
Male 4.9 (2.6–7.9) 2.46 (1.34–4.48) 0.82 (0.29–1.82) 0.81 (0.30–1.71) 5.0 (2.9–7.7) 9.9 (6.7–13.8)
Age (15,50) 4.0 (2.3–6.2) 3.00 (1.74–5.03) reference reference 3.7 (2.1–5.6) 7.7 (5.3–10.3)
(50,Inf) 3.5 (1.1–7.1) 4.17 (1.46–10.84) 1.53 (0.45–3.94) 1.41 (0.47–4.16) 4.6 (1.9–8.1) 8.1 (4.3–12.5)
HIV Non-HIV 8.5 (5.0–12.7) 1.29 (0.76–2.16) reference reference 7.1 (4.3–10.8) 15.6 (11.3–20.8)
PLHIV 1.3 (0.3–3.0) 12.79 (3.77–41.16) 5.33 (1.90–11.92) 4.81 (1.65–12.82) 2.4 (1.0–4.1) 3.7 (1.9–6.0)
RR risk ratio, PLHIV people living with HIV
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with HIV. Our analysis of TB care-seeking, diagnosis
and treatment outcome cascades also showed substantial
differences between settings, and meaningful losses be-
fore the first symptom developed and care-seeking.
Taken together, these findings suggest that important
opportunities exist to identify people with tuberculosis
earlier in their disease course through screening and
community-based active case finding interventions, po-
tentially improving individual outcomes and reducing
transmission.
TB disease prior to care-seeking, including the asymp-
tomatic phase, is beyond the reach of passive case-
finding: improvements in diagnosis and retention at the
clinic will not shorten these delays nor avert deaths dur-
ing this phase. Cases that are truly asymptomatic can
only be found by active approaches to screening based
on exposure, chest X-ray or other novel rule-in tests -
based in either the community or clinics. The symptom-
atic period prior to care seeking would be amenable to
intervention by symptom-based screening approaches
and potentially health-messaging or improved access to
care. Understanding the duration of these phases and
their contributions to transmission and mortality is
therefore key to understanding the relative potential
benefits of more active approaches to finding cases [26].
Although, between 25% and 50% of the total duration
(and likely a higher proportion of transmission and pre-
treatment mortality) occurs once those with TB have
started seeking care, when improvements in passive
case-finding and reductions in pre-treatment loss-to-
follow-up (which has been observed a 13% in Asia and
18% in African settings) can help [28]. While there is
considerable consistency between settings in our results,
the reasons for the longer durations of asymptomatic
disease in Asian settings are not clear, and seem not to
relate to HIV prevalence. These may include cultural
factors around recognition of disease or willingness to
report it, differences in strains, or differences in cough
associated with smoking or air quality which may mask
TB symptoms. It is noteworthy that these settings also
have longer total durations of TB disease. Future work
could include the development of hierarchical models,
which would pool data across countries and potentially
smooth out some of these differences.
Our method also generates estimates of TB incidence:
using literature estimates of TB disease mortality and
self-cure rates, we inferred the proportions that fail to
reach notification. Our incidence estimates are similar to
those of WHO [1], which is not surprising since these
are based on the same data. Our estimates have lower
uncertainty, which may reflect under-estimation of un-
certainty by our approach in not including uncertainty
in TB mortality rates.
Our approach has quantified aspects of TB natural his-
tory that are potentially important but poorly charac-
terised, relying on historical or anecdotal data. For
example, mathematical models of TB transmission have
from the outset often included progression in smear
Table 3 Epidemiological estimates by HIV status, Kenya and Blantyre. TB incidence, case detection ratio, and smear-stratified
symptom duration by HIV status for Kenya and Blantyre, Malawi
Kenya Blantyre
HIV status Non-HIV PLHIV Non-HIV PLHIV
Background mortality μ μ + HIV-related mortality μ μ + HIV-related mortality




5% per month Smear−: 50%/10 years
Smear+: 70%/10 years
5% per month
All TB regardless of symptomatic or not
Time asymptomatic, month 10.35 (8.41–
12.84)





7.79 (5.78– 9.99) 6.49 (4.94–8.11) 16.27 (11.59–
21.53)
3.76 (1.81–6.07) 3.26 (1.76–5.03)
Case-detection ratio 69% (59–81%) 84% (77–91%) 71% (63–80%) 76% (64–88%) 94% (88–98%) 84% (74–93%)













3.99 (2.52–5.56) 3.27 (2.16–4.40) 7.47 (4.53–11.05) 2.44 (1.00–4.25) 2.11 (0.95–3.49)
Case-detection ratio 83% (75–91%) 90% (85–95%) 76% (67–84%) 88% (79–95%) 95% (90–98%) 85% (75–94%)








μ: background mortality based on the World Population Prospects, 2016 for Kenya and 2019 for Blantyre (Malawi)
HIV-related mortality: AIDS-related deaths/PLHIV for aged 15 and above from the UNAIDS data
5% per month (0.61 per year): an extreme case for gold miner in pre-ART era [26]
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status [25]. In an analysis of cross-sectional data, this
smear conversion rate is confounded with the propor-
tion of individuals who are smear-positive from very
early in their disease. Our posterior shows a high correl-
ation between these parameters, but the gradient of ini-
tial smear-positivity with respect to conversion rate is
broadly consistent between settings. Our pooled esti-
mate should be useful for modellers wishing to paramet-
rize joint uncertainty around these features.
There has been an increased realisation that TB
disease is less dichotomous and more dynamic than con-
ventional paradigms have allowed [8]. Our findings com-
plement work in this area by describing the dynamics
through asymptomatic disease and different levels of in-
fectiousness while symptomatic. (We have used the term
asymptomatic TB as synonymous with the term sub-
clinical TB used in some discussions.) The substantial
fraction of time spent asymptomatic means there is the
potential for this phase to make important contributions
to TB transmission. The key unknown factor here is the
relative infectiousness of the asymptomatic phase; with-
out this quantity, we are not able to estimate this contri-
bution. While some evidence suggests that the natural
history of TB disease may include progression and re-
mission [8], we have assumed a one-way progression
through the asymptomatic phase, smear status, and
care-seeking - we were limited here by our reliance on
cross-sectional data. However, our transitions between
these cruder states could be considered as characterising
the net average transitions in a population experiencing
more complex dynamics among sub-states. This means
that our estimated durations are best interpreted as
mean time spent in each state and that proportions de-
veloping symptoms (e.g., Fig. 4) require caveat: with
symptom reversion, the proportion ever reaching symp-
toms will be higher. Our sensitivity analysis, fitting our
model to simulated data from models that include rever-
sion as well as progression, explores these effects (see
Additional file 1 section E3). More data constraining
symptom dynamics would be necessary to meaningfully
include additional complexity around this in our inferen-
tial approach. Including questions in TB prevalence sur-
veys to distinguish current and historical symptoms and
care could help quantify intermittency. Similarly, there
may be heterogeneity in disease-course, which we were
not able to consider. For example, there may be a mix-
ture of TB disease types with differing symptom trajec-
tories or rates of progression.
HIV-associated TB has long been known to have a
more rapid TB disease progression [10], but data to
quantify this has been limited [29], and most models
and estimates of TB burden assume the same case detec-
tion ratio in PLHIV as among HIV-negative people [30].
We were able to provide the first empirical estimate of
this quantity. Our sensitivity analysis considered from
zero excess TB/HIV mortality through to an extremely
high level and consistently found TB case-detection ra-
tios for PLHIV that were higher than for HIV-negative
people. We were not able to stratify by ART status, but
increases in ART coverage and regular healthcare visits
for people on ART may have helped improve TB case
detection among PLHIV. We found an asymptomatic
TB disease duration shorter than five months in people
living with HIV, and the delays from the first symptom
developed to case-detection also much shorter than
those for HIV-negative people. The duration of TB dis-
ease in PLHIV has been suggested to decrease with CD4
cell count [31]; our results are consistent with this, but
lack of CD4 data meant was not able to test this hypoth-
esis. For those countries with high HIV-prevalence that
lacked HIV-stratified data, our durations are expected to
be lower than those experienced by HIV-negative
people.
Comparing our model estimates of the delays from TB
onset to notification with empirical estimates from P:N
ratios, we find that empirical estimates systematically
overestimate duration. This is because the empirical esti-
mator implicitly assumes that all prevalent TB ends in
notification, whereas in the model (and reality) self-cure
and death are possible outcomes [32]. These unobserved
competing events add to the rate at which individuals
cease being prevalent, thus shortening the prevalent dur-
ation. The discrepancy between empirical and model es-
timates is largest where the CDR is lowest. Under-
notification, e.g. in settings with large private sectors can
further overestimate durations.
The duration of symptomatic TB is necessarily shorter
than the total duration. Empirical estimates of TB dur-
ation based on TB prevalence surveys that used symp-
toms as an entry point to bacteriological testing [33]
may therefore be biassed. Where symptoms alone are
used to rule in, the empirical P:N ratio is measuring the
duration of the symptomatic phase rather than the total
duration of TB disease. The range of symptoms used
can also affect estimated durations, with broader defini-
tions shortening the duration of the asymptomatic
phase. All the surveys we used either applied chest X-ray
OR symptoms to rule-in for bacteriological testing while
most of them considered only cough of ≥ 2 weeks and
some included more symptoms (e.g. Tanzania used five
symptoms [18]) for the symptom screening.
A limitation of our approach is that it relies on self-
report for defining whether individuals have symptoms or
have begun seeking care. Stigma, fear of diagnosis, or ex-
pectations of treatment may all affect and influence partic-
ipants' willingness to report symptoms, even if they are
recognised; recognition of symptoms may itself be influ-
enced by cultural and epidemiological factors [34, 35].
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Recall bias may play a role in limiting the accuracy of re-
ports of care-seeking. We were limited in our ability to de-
tect effects that may be real, such as age-dependency in
durations, and to investigate smear status while asymp-
tomatic, due to the relatively small numbers of TB cases
found in prevalence surveys. Our projections of growth or
decline rely solely on trends in notification data; where
notification trends reflect changes in routine case finding
performance, our projections of underlying incidence and
prevalence trends may be incorrect. Finally, while most of
our parameters have incorporated prior uncertainty, being
treated as random variables in a Bayesian framework, we
treated TB mortality and self-cure as fixed, which may
underestimate uncertainty in our estimates.
A strength of our approach is that we have adopted a
rigorous Bayesian framework, which includes uncer-
tainty in inputs and outputs and could easily be general-
ised for use on other national or subnational data, and
potentially developed as a software package. Unlike most
approaches to P:N analyses, we do not make an assump-
tion of equilibrium. Our assumption is the slightly more
general and realistic constant rate of decline, which is an
additional output.
Conclusion
Active approaches to TB screening and case-finding
should be considered in high TB burden settings, where
up to 4 to 12months with the infectious bacteriologic-
ally positive disease is spent without symptoms, and a
comparable time again with symptoms before care-
seeking initiation.
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